Moreover, there are many studies describing the potential clinical utility of mutation testing in the liquid biopsy of NSCLC patients in ROS1 [128,129], MET [130,131], and BRAF [119,131] genes. The gene discussed is BRAF; the disease is non-small cell lung carcinoma.